AUG 17, 2018
Should Baseline Characteristics Affect Treatment Choice for PDR?
ASRS 2018
04:50
Retina/Vitreous
In this interview from ASRS 2018, Dr. Susan Bressler discusses how patient baseline characteristics affect the outcomes of patients who are being treated with 2 proliferative diabetic retinopathy (PDR) treatments: ranibizumab and panretinal photocoagulation (PRP). None of the 25 patient characteristics that were assessed showed that PRP was superior to ranibizumab at 2 years. Instead, patients with high blood pressure or advanced PDR exhibited a greater improvement on ranibizumab, compared with PRP. According to Dr. Bressler, although PRP is still a good option, some patients may benefit more from regular anti-VEGF treatment over 2 years.
Relevant Financial Disclosures: Dr. Susan Bressler receives grant support from Genentech